Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic canc...
Revolution beats expectations | ApexOnco - Clinical Trials news and analysis
Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic cancer, but it's already calling the results transformative.
Author: Oncology Pipeline
Read Original Article